Orally administered BZL-sRNA-20 oligonucleotide targeting TLR4 effectively ameliorates acute lung injury in mice

  • Impact factors: 10.372
  • Publication: Science China-Life Sciences
  • Author:Zhao Dandan, Qin Yuhao, Liu Jiaqi, Tang Kegong, Lu Shuaiyao, Liu Zirui, Lin Yexuan, Zhang Cong, Huang Fengming, Chang Jiahui, Li Chang, Tian Mingyao, Ma Yiming, Li Xiaoyun, Zhou Congzhao, Li Xiao, Peng Xiaozhong, Jin Ningyi, Jiang Chengyu
  • DOI citation-doi:10.1007/s11427-022-2219-0
  • Date:2023-02-13

The global COVID-19 pandemic emerged at the end of December 2019. Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are common lethal outcomes of bacterial lipopolysaccharide (LPS), avian influenza virus, and SARS-CoV-2. Toll-like receptor 4 ( TLR4 ) is a key target in the pathological pathway of ARDS and ALI. Previous studies have reported that herbal small RNAs (sRNAs) are a functional medical component. BZL-sRNA-20 (Accession number: B59471456; Family ID: F2201.Q001979.B11) is a potent inhibitor of Toll-like receptor 4 ( TLR4 ) and pro-inflammatory cytokines. Furthermore, BZL-sRNA-20 reduces intracellular levels of cytokines induced by lipoteichoic acid (LTA) and polyinosinic-polycytidylic acid (poly (I:C)). We found that BZL-sRNA-20 rescued the viability of cells infected with avian influenza H5N1, SARS-CoV-2, and several of its variants of concern (VOCs). Acute lung injury induced by LPS and SARS-CoV-2 in mice was significantly ameliorated by the oral medical decoctosome mimic (bencaosome; sphinganine (d22:0)+BZL-sRNA-20). Our findings suggest that BZL-sRNA-20 could be a pan-anti-ARDS ALI drug.

Related Products

$400.00$500.00

$400.00$500.00

$400.00$500.00

$400.00$500.00

$400.00$500.00

$400.00$500.00

$400.00$500.00

EK1392

$350.00$450.00

EK1242

$350.00$450.00

EK1C01

$350.00$450.00

EK1341

$350.00$450.00

EK1334

$350.00$450.00

EK2295

$350.00$450.00

$350.00$450.00

EK2100

$350.00$450.00

EK1360

$350.00$450.00

Hot products

Hot citation